By slight changes in structure, agents with improved relaxivity and altered distribution have been developed, with further research likely in this area. Gadavist (Gadovist, outside the U.S.) intrinsically has higher relaxivity than the other extracellular agents. MultiHance, which demonstrates transient protein binding, likewise has higher relaxivity (40% at 1.5 T, equivalent to double dose, the highest in this class of agents) and in addition partial hepatobiliary excretion, both due to addition of a phenyl moiety. Fig. 47.1 illustrates the improved enhancement of a brain metastasis at 1.5 T with MultiHance
. Fig. 47 .2 illustrates, using a hepatobiliary gadolinium chelate, a liver metastasis prior to ( Fig. 47.2a) , immediately following (Fig. 47.2b) , and in the hepatobiliary phase after ( Fig. 47.2c ) injection. Hepatobiliary uptake and excretion of the agent are illustrated, with sustained enhancement of normal liver, opacification of the gallbladder, and slightly improved visualization of a liver metastasis (arrow) on the delayed image. High-quality breath-hold imaging in all three orthogonal planes is possible in the hepatobiliary phase, providing improved detection of liver metastases, such as that seen immediately below the dome of the diaphragm (Fig. 47.2d Some of the newer gadolinium chelates have advantages as well in contrast-enhanced MR angiography. For example, vessel signal intensity has been shown to be markedly improved with both Gadavist and MultiHance, the former principally due to its higher formulation concentration (1 molar) and the latter due to transient albumen binding, compared with more conventional agents. These improvements, together with technologic advances in equipment design, have made possible high resolution whole-body 3D contrast-enhanced MR angiography ( Fig. 47.3) , with five 3D datasets, slightly overlapping, acquired in immediate succession following a single intravenous contrast dose. 
